对间变性淋巴瘤激酶基因融合变异的非小细胞肺癌患者的治疗策略

Therapeutic strategy of non-small cell lung cancer patients with anaplastic lymphoma kinase fusion gene variants

目前,全球范围内的肺癌发病率都趋升高。大多数非小细胞肺癌患者在就诊时已处于中、晚期,给治疗带来了巨大的挑战。以克唑替尼为代表的间变性淋巴瘤激酶酪氨酸激酶抑制剂对间变性淋巴瘤激酶基因融合变异阳性的晚期非小细胞肺癌患者的疗效及耐受性良好,表明基于间变性淋巴瘤激酶基因融合变异等分子标志物的肺癌分子靶向治疗模式已经在临床上得以建立和实际应用。

The incidence of lung cancer has significantly increased worldwide at present. Most of the patients with non-small cell lung cancer （NSCLC） are in the advanced stage when diagnosed, which brings a huge challenge to the therapeutic strategy of NSCLC. Anaplastic lymphoma kinase （ALK）-tyrosine kinase inhibitors （TKI） represented by crizotinib have showed good efficacy and tolerability in clinical practice. With the aim of overcoming crizotinib-acquired resistance, different second generation of ALK-TKIs have been recently evaluated and demonstrated fine research results according to several clinical trials. Molecular targeting and individualized treatment mode based on the molecular markers of the ALK fusion gene mutation of lung cancer has been established and applied in clinical practice.